Literature DB >> 29051150

Lymphoma "benchmark" or "bench-smudge"?

Sarah C Rutherford1, John P Leonard1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29051150     DOI: 10.1182/blood-2017-08-800730

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.

Authors:  David Sermer; Connie Batlevi; M Lia Palomba; Gunjan Shah; Richard J Lin; Miguel-Angel Perales; Michael Scordo; Parastoo Dahi; Martina Pennisi; Aishat Afuye; Mari Lynne Silverberg; Caleb Ho; Jessica Flynn; Sean Devlin; Philip Caron; Audrey Hamilton; Paul Hamlin; Steven Horwitz; Erel Joffe; Anita Kumar; Matthew Matasar; Ariela Noy; Colette Owens; Alison Moskowitz; David Straus; Gottfried von Keudell; Ildefonso Rodriguez-Rivera; Lorenzo Falchi; Andrew Zelenetz; Joachim Yahalom; Anas Younes; Craig Sauter
Journal:  Blood Adv       Date:  2020-10-13

2.  Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.

Authors:  Sara Harrysson; Sandra Eloranta; Sara Ekberg; Gunilla Enblad; Tarec C El-Galaly; Birgitta Sander; Kristina Sonnevi; Per-Ola Andersson; Mats Jerkeman; Karin E Smedby
Journal:  Br J Haematol       Date:  2022-04-25       Impact factor: 8.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.